Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.37 |
| ▸ | AR | P10275 | 3/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 2/20 | 0.33 |
| ▸ | FNTB | P49356 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818856 | 0.92 | NR3C1 (0.43) | NR3C1TDP1MEN1KMT2APGR | |
| SCHEMBL4818843 | 0.92 | NR3C1 (0.43) | NR3C1TDP1MEN1KMT2APGR | |
| SCHEMBL4981552 | 0.88 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2APGR | |
| SCHEMBL4982043 | 0.88 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2APGR | |
| SCHEMBL4255031 | 0.88 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2APGR | |
| SCHEMBL4822515 | 0.88 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2APGR | |
| SCHEMBL4818715 | 0.84 | NR3C1 (0.41) | NR3C1TDP1MEN1KMT2APGR | |
| SCHEMBL4815685 | 0.84 | NR3C1 (0.41) | NR3C1TDP1MEN1KMT2APGR | |
| SCHEMBL5393545 | 0.84 | NR3C1 (0.41) | NR3C1TDP1MEN1KMT2APGR | |
| SCHEMBL4819437 | 0.83 | NR3C1 (0.41) | NR3C1TDP1MEN1KMT2APGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027237-A1 | Processes for preparations of 9,11-epoxy steroids and intermediates useful therein | NG JOHN S | 2008-01-31 | — | — | US | claimed |
| US-20040191874-A1 | Process for preparation of 9, 11-epoxy steroids and intermediates useful therein | G.D. SEARLE & COMPANY | 2004-09-30 | — | — | US | claimed |
| US-20040067917-A1 | Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein | G. D. SEARLE & COMPANY | 2004-04-08 | — | — | US | claimed |
| US-20030100541-A1 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein | NG JOHN S (US) | 2003-05-29 | — | — | US | claimed |
| US-20030055274-A1 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein | G.D. SEARLE & COMPANY | 2003-03-20 | — | — | US | claimed |
| US-20020042507-A1 | Process for preparation of 9,11-epoxy steroids and intermediates useful therein | NG JOHN S (US) | 2002-04-11 | — | — | US | claimed |
| US-20020019522-A1 | Processes for preparation of 9-11, epoxy steroids and intermediates useful therein | NG JOHN S (US) | 2002-02-14 | — | — | US | claimed |
| US-20020016455-A1 | Processes for preparation of 9,11- epoxy steroids and intermediates useful therein | NG JOHN S (US) | 2002-02-07 | — | — | US | claimed |
| EP-1170299-A2 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein | G.D. Searle & Co. (US) | 2002-01-09 | — | — | EP | claimed |
| US-20080027237-A1 | Processes for preparations of 9,11-epoxy steroids and intermediates useful therein | NG JOHN S | 2008-01-31 | — | — | US | disclosed |
| EP-1148061-B1 | Epoxidation process | SEARLE LLC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-0973791-B1 | PROCESS FOR THE PREPARATION OF AN EPOXY COMPOUND | SEARLE LLC (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070060746-A1 | PROCESSES FOR PREPARATION OF 9,11 EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN | G.D. SEARLE, LLC (FORMERLY NAMED G.D. SEARLE & CO.) | 2007-03-15 | — | — | US | disclosed |
| US-7129345-B2 | Keto-substituted steroid compounds | PHARMACIA CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-6335441-B1 | 5β-cyano-substituted steroid compounds | G.D. SEARLE & CO. | 2002-01-01 | — | — | US | disclosed |
| US-6331622-B1 | Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein | G.D. SEARLE & CO. | 2001-12-18 | — | — | US | disclosed |
| EP-1148061-A2 | Process for preparation of 9, 11- epoxy steroids and intermediates useful therein | G.D. SEARLE & CO. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6258946-B1 | CHEMICAL INTERMEDIATE FOR DIURETIC | G. D. SEARLE & CO. | 2001-07-10 | — | — | US | disclosed |
| US-6180780-B1 | STEROIDS AND INTERMEDIATES AS DIURETICS | G.D. SEARLE & CO. | 2001-01-30 | — | — | US | disclosed |
| US-5981744-A | REMOVING AN 11-ALPHA LEAVING GROUP FROM STARTING COMPOUND TO GENERATE A DOUBLE BOND BETWEEN THE 9- AND 11-CARBON ATOMS | G. D. SEARLE AND CO. (US) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100541-A1 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein | CYP4A11, HSD11B1, DHCR7 | NR3C1 36/4885TDP1 4462/4885MEN1 4242/4885 |
| US-20040067917-A1 | Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein | CYP4A11, HSD11B1, HSD3B1 | NR3C1 47/4885TDP1 4299/4885MEN1 4118/4885 |
| US-20080027237-A1 | Processes for preparations of 9,11-epoxy steroids and intermediates useful therein | CYP4A11, CYP11B1, CYP17A1 | NR3C1 89/4885TDP1 4310/4885MEN1 1070/4885 |
| US-20030055274-A1 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein | CYP4A11, HSD11B1, DHCR7 | NR3C1 45/4885TDP1 4308/4885MEN1 4196/4885 |
| US-20070060746-A1 | PROCESSES FOR PREPARATION OF 9,11 EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN | DHCR7, CYP4A11, HSD11B1 | NR3C1 57/4885TDP1 4190/4885MEN1 3051/4885 |
| US-20020019522-A1 | Processes for preparation of 9-11, epoxy steroids and intermediates useful therein | CYP4A11, HSD11B1, DHCR7 | NR3C1 32/4885TDP1 4485/4885MEN1 4344/4885 |
| US-20020042507-A1 | Process for preparation of 9,11-epoxy steroids and intermediates useful therein | CYP4A11, HSD11B1, DHCR7 | NR3C1 42/4885TDP1 4522/4885MEN1 4284/4885 |
| US-20020016455-A1 | Processes for preparation of 9,11- epoxy steroids and intermediates useful therein | CYP4A11, HSD11B1, DHCR7 | NR3C1 36/4885TDP1 4462/4885MEN1 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.